British journal of haematology · 2018
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Drevon Louis, Marceau Alice, Maarek Odile, Cuccuini Wendy, Clappier Emmanuelle, Eclache Virginie, Cluzeau Thomas, Richez Valentine, Berkaoui Inès, Dimicoli-Salazar Sophie, Bidet Audrey, Vial Jean-Philippe, Park Sophie, Vieira Dos Santos Christina, Kaphan Eléonore, Berthon Céline, Stamatoullas Aspasia, Delhommeau François, Abermil Nassera, Braun Thorsten, Sapena Rosa, Lusina Daniel, Renneville Aline, Adès Lionel, Raynaud Sophie, Fenaux Pierre
Аннотация
Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following: white blood cell count >10 × 109 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fifty-four patients (39·1%) had MP features: 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33·3% vs. 12·0% in non-MP, P = 0·047), ASXL1 (66·7% vs. 42·3%, P = 0·048) and STAG2 mutations (77·8% vs. 21·7%, P = 0·006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0·15) and 39 months (P = 0·085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms.
Предметные рубрики MeSH
AdultAgedAntigens, NuclearAntimetabolites, AntineoplasticCell Cycle ProteinsChromosomes, Human, Pair 8Disease ProgressionEnhancer of Zeste Homolog 2 ProteinFemaleHumansMiddle AgedMyelodysplastic SyndromesMyeloproliferative DisordersRepressor ProteinsRetrospective StudiesSurvival AnalysisTrisomyCohesins